PRL and myeloid sarcoma: Low PRL levels associate with a higher prevalence of type 2 diabetes (T2D), insulin resistance, glucose intolerance, metabolic syndrome (MS), adipose tissue (AT) dysfunction, β-cell dysfunction, non-alcoholic fat liver disease (NAFLD), and cardiovascular events, whereas moderately high PRL levels correlate with metabolic protection in all these instances (Table 1).